KMTS KESTRA MEDICAL TECHNOLOGIES, LTD. Insider Trading

Director Cohen buys 10,000 KMTS shares at $19.98, holding +24.4%; stock down -34.6% from 52-week high.

Director Raymond W Cohen purchased 10,000 shares of KESTRA MEDICAL TECHNOLOGIES at $19.98 on 2026-03-26, increasing his holdings by 24.4% to 50.9K shares. The purchase occurs against a backdrop of significant recent price deterioration: the stock trades at $18.33, down -34.6% from its 52-week high of $28.01 and down -21.3% over the prior 30 days. Cohen's prior buy at KMTS on 2025-03-07 generated positive returns (+36.9% at 30 days, +17.4% at 90 days), establishing a 100% well-timed rate at this ticker. However, the company remains unprofitable with a net income of $-34.2M against quarterly revenue of $24.6M, and the stock has declined -32.0% over the 90-day window, creating tension between the insider's historical timing success at KMTS and the current deteriorating fundamentals and price trajectory.

Director Cohen buys 17,000 shares (17.0K) of KMTS at $17.00; holdings increase 71.1% to 40,903 shares.

Director Raymond W. Cohen purchased 17,000 shares of Kestra Medical Technologies at $17.00, increasing his holdings by 71.1% to 40,903 shares post-transaction. The purchase occurred at a price 30.5% below the 52-week high of $25.70, though the stock is up 23.0% over the past 30 days. Cohen's cross-ticker track record shows one prior sale with a 90-day well-timed rate of 100.00%, indicating historically favorable timing. The company's fundamentals present a mixed picture: revenue growth of 115.0% year-over-year demonstrates strong top-line expansion, but the company remains unprofitable and operates with a market cap of $917.1M. The substantial 71.1% increase in Cohen's personal stake warrants investor attention to understand the basis for this significant position expansion.